JCR files for Japanese approval of agalsidase beta biosimilar

Biosimilars/News | Posted 06/10/2017 post-comment0 Post your comment

Japan-based JCR Pharmaceuticals (JCR) announced on 29 September 2017 that it had applied for Japanese regulatory approval for its agalsidase beta biosimilar (JR‑051).

Fabry Agalsidase beta V17J06

The product is a proposed biosimilar version of Genzyme’s Fabry disease treatment Fabrazyme (agalsidase beta). Fabry disease is an inherited disease caused by the lack of an enzyme called alpha-galactosidase A, in the body. The rare disease is characterized by pain in the extremities, clouding of the cornea, renal failure and cardiac dysfunction. Approximately 600 patients in Japan and 10,000 worldwide suffer from the disease, according to JCR.

Alpha-galactosidase is a glycoside hydrolase enzyme that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. It is encoded by the GLA gene. Two recombinant forms of alpha-galactosidase exist, called agalsidase alpha and agalsidase beta.

JCR is developing the agalsidase beta biosimilar (JR‑051) in collaboration with GlaxoSmithKline for Japan and Asia-Oceania territories. The companies announced positive results for their pharmacokinetics study in February 2015, which they said ‘demonstrated the bioequivalence of JR-051’. In addition, the companies say that ‘the phase II/III clinical trial with Fabry patients initiated in May 2015 generated results that demonstrated equivalence in efficacy and safety of JR-051 compared with the innovator product’.

If approved, JCR says JR‑051 will be the first domestic enzyme replacement therapy (ERT) available to Fabry patients. It will also be the first product to come out of JCR’s lysosomal storage disease pipeline. Other ERT products under development include JR‑141 (blood–brain barrier penetrating therapeutic enzyme for Hunter syndrome) and JR‑162 (J-Brain Cargo-applied therapeutic enzyme for Pompe disease).

JCR already has a biosimilar approved in Japan. Epoetin alfa BS (epoetin alfa biosimilar 1) was approved by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) in January 2010 [1].

Related articles
Nichi-Iko gains Japanese approval for infliximab biosimilar

Daiichi Sankyo ends deal with Coherus for etanercept biosimilar in Japan

1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Japan [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Oct 6]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Japan

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2017 Pro Pharma Communications International. All Rights Reserved.

Source: JCR

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010